CRSwNP patients exhibiting Th2 inflammatory reactions and high serum IgE levels may benefit from biological agents, which have shown the advantages of high efficiency and safety in adult CRS clinical research and may be extended to pediatric patients in the future. This evidence concerns the gene IGHE and chronic rhinosinusitis with nasal polyps.